Certara (NASDAQ:CERT) Stock Price Up 10.5% – Still a Buy?

Certara, Inc. (NASDAQ:CERT) shares were up 10.5% on Tuesday . The company traded as high as $5.61 and last traded at $5.7550. Approximately 396,739 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 3,459,407 shares. The stock had previously closed at $5.21.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on CERT shares. TD Cowen reissued a “buy” rating on shares of Certara in a research report on Thursday, February 26th. Leerink Partners reaffirmed an “outperform” rating and issued a $10.00 target price on shares of Certara in a report on Thursday, February 26th. BMO Capital Markets reduced their target price on shares of Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Certara in a report on Friday, May 29th. Finally, Stephens reduced their target price on shares of Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $8.85.

Certara Stock Up 15.5%

The stock has a market capitalization of $935.75 million, a PE ratio of -59.93 and a beta of 1.49. The firm’s fifty day moving average is $5.58 and its 200-day moving average is $7.15. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.02). The firm had revenue of $106.92 million for the quarter, compared to analysts’ expectations of $106.13 million. Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The company’s revenue for the quarter was up .8% on a year-over-year basis. During the same period in the prior year, the company earned $0.14 earnings per share. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. On average, equities research analysts predict that Certara, Inc. will post 0.24 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. grew its position in Certara by 2,733.3% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after buying an additional 2,870 shares during the period. Osaic Holdings Inc. lifted its stake in shares of Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after buying an additional 1,175 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of Certara by 499.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after buying an additional 4,930 shares during the period. Chicago Partners Investment Group LLC purchased a new position in Certara during the first quarter worth approximately $78,000. Finally, Kera Capital Partners Inc. purchased a new position in Certara during the first quarter worth approximately $80,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.